AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20350745
Drug: Foot gel
RxNorm normalized name: CLOTRIMAZOLE 0.01 kg in 1 kg TOPICAL GEL [Forticept Antifungal Foot Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot gel pads
Trial: 20350745
Drug: No foot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No foot gel pads
Trial: 18669993
Drug: Individual Placement
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual Placement and Support (IPS) + Treatment as Usual (TAU)
Trial: 14639098
Drug: Adenosine injection
RxNorm normalized name: adenosine Injection
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine injection (doses not specified)
Trial: 6507184
Drug: Naloxone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.4 mg)
Trial: 10888041
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy with 6 mg/m2 of cisplatin and split-course radiotherapy (Group 2)
Trial: 10888041
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy with two cycles of etoposide, ifosfamide, and cisplatin followed by split-course radiotherapy (Group 3)
Trial: 20011881
Drug: Epsilon-aminocaproic acid
RxNorm normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon-aminocaproic acid (EACA) 24 g in 250 ml saline solution
Trial: 20011881
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 ml saline solution)
Trial: 11604268
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid added to enteric-coated matrix granules and tablet matrix
Trial: 9819787
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen (Premarin) 0.625 mg/day orally plus medroxyprogesterone acetate (Farlutal) 10 mg/day orally (RHRT group)
Trial: 9819787
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (NRHRT group)
Trial: 7650533
Drug: Total lifetime
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total lifetime dose of ethanol
Trial: 2523660
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral isradipine
Trial: 2523660
Drug: Isradipine treatment
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine treatment over 12 weeks
Trial: 848803
Drug: Ragweed inhalation
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ragweed inhalation challenge
Trial: 31808584
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LLLT and fluoride varnish (L + FV)
Trial: 16830018
Drug: Propofol 1%
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 1% premixed with 40 mg of lidocaine
Trial: 16830018
Drug: Propofol 1%
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 1% given 60 seconds after 40 mg of lidocaine
Trial: 16830018
Drug: Venous occlusion
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venous occlusion for 60 seconds with lidocaine 1% (40 mg) followed by propofol
Trial: 7901024
Drug: Fenspiride hydrochloride
RxNorm normalized name: fenspiride hydrochloride
DrugBank: Fenspiride (DB08979)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenspiride hydrochloride (80 mg) administered IV
Trial: 7901024
Drug: Fenspiride hydrochloride
RxNorm normalized name: fenspiride hydrochloride
DrugBank: Fenspiride (DB08979)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenspiride hydrochloride (80 mg) administered orally
Trial: 7901024
Drug: Fenspiride hydrochloride
RxNorm normalized name: fenspiride hydrochloride
DrugBank: Fenspiride (DB08979)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenspiride hydrochloride (IV and oral)
Trial: 26895001
Drug: Tumescent lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tumescent lidocaine without liposuction at a dosage of 28 mg/kg
Trial: 26895001
Drug: Tumescent lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tumescent lidocaine with liposuction at a dosage of 45 mg/kg
Trial: 1095122
Drug: L-Dopa
RxNorm normalized name: L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: L-Dopa
Trial: 19014156
Drug: Flapless immediately
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flapless immediately loaded implants
Trial: 19014156
Drug: Conventional implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional implants (submerged or unsubmerged)
Trial: 12683470
Drug: Nefazodone (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (300-600 mg per day in two divided doses)
Trial: 19217168
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nefazodone and psychotherapy
Trial: 12683470
Drug: Nefazodone (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (alone or in combination with CBASP)
Trial: 7560617
Drug: Captopril therapy
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril therapy
Trial: 1532672
Drug: FUDR (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUDR (0.05 to 1.7 mg/kg/d) alone or combined with 5-FU and leucovorin
Trial: 1532672
Drug: Combined intraarterial
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intraarterial treatment with LCV
Trial: 1532672
Drug: Regional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional treatment
Trial: 2992278
Drug: Estradiol transdermal
RxNorm normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol transdermal system, 0.1 mg/day
Trial: 2992278
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens, 0.625 mg/day
Trial: 2992278
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens, 1.25 mg/day
Trial: 12535810
Drug: Spironolactone treatment
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone treatment
Trial: 23830709
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy (SMT) targeted to the C5‐C6 spinal segment
Trial: 23830709
Drug: Sham spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham spinal manipulative therapy
Trial: 12221393
Drug: 2% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% CHX solution + a 25% CHX‐containing controlled‐release device
Trial: 12221393
Drug: Ca(OH)(2)+ 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca(OH)(2)+ 0.2% CHX gel
Trial: 12221393
Drug: 0.2% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% CHX gel
Trial: 7976413
Drug: Metyrapone (11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (11 beta‐hydroxylase inhibitor) followed by growth hormone releasing hormone (1 microgram kg‐1 body wt)
Trial: 7976413
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by growth hormone releasing hormone (1 microgram kg‐1 body wt)
Trial: 29095263
Drug: Phenylephrine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (0.5 mL/kg/h, 5 mg/50 mL)
Trial: 19735542
Drug: Integrative Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Medicine (IM) care with seven treatment sessions from two different types of complementary therapies over ten weeks.
Trial: 19735542
Drug: Integrative Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Medicine (IM) care
Trial: 19735542
Drug: Conventional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional care (advice and prescription of analgesics)
Trial: 9028311
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy followed by autologous hematopoietic progenitor cell transplantation with fractionated total body irradiation, etoposide (VP) 60 mg/kg, and cyclophosphamide (Cy) 100 mg/kg.
Trial: 9028311
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy followed by autologous hematopoietic progenitor cell transplantation with BCNU 15 mg/kg, VP 60 mg/kg, and Cy 100 mg/kg.
Trial: 9028311
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy followed by autologous hematopoietic progenitor cell transplantation with CCNU 15 mg/kg, VP 60 mg/kg, and Cy 100 mg/kg.
Trial: 2438451
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight dextran solution
Trial: 31298289
Drug: Ultrasound-guided perineural
RxNorm normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided perineural PRP injection and medical treatment
Trial: 26654906
Drug: Microbial cell
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microbial cell preparation (daily dosage of 6 × 10^10 CFU)
Trial: 18227766
Drug: Nonpenetrating very
RxNorm normalized name: Primula veris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpenetrating very deep sclerectomy (NPVDS) with reticulated hyaluronic acid implant (SKGEL)
Trial: 11298610
Drug: 75 microg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 microg/kg/d intravenous (i.v.) anti-D
Trial: 11298610
Drug: 50 microg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg/kg/d intravenous (i.v.) anti-D
Trial: 9253562
Drug: Ondansetron 0.1
RxNorm normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.1 mg kg‐1
Trial: 9253562
Drug: Droperidol 75
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droperidol 75 micrograms kg‐1 and Ondansetron 0.1 mg kg‐1
Trial: 8310137
Drug: Conformal pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conformal pelvic radiotherapy (dose levels of 30‐38 Gy)
Trial: 8310137
Drug: Conformal pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conformal pelvic radiotherapy (dose levels of 56‐65 Gy)
Trial: 28097317
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy plus 6 months of androgen deprivation therapy
Trial: 26085515
Drug: HSF +
RxNorm normalized name: Hydroxyethyl Starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSF + DHA diet (3.45 g DHA/d and 0.5 g EPA/d)
Trial: 23663917
Drug: Tailored regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored regimen (daily pills until three consecutive days bleeding triggers a 3‐day pill‐free interval) of Microgynon 30® (ethinyl oestradiol 30 mcg, levonorgestrel 150 mcg)
Trial: 23663917
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (21 daily pills followed by a 7‐day pill‐free interval) of Microgynon 30® (ethinyl oestradiol 30 mcg, levonorgestrel 150 mcg)
Trial: 20415935
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen arginate (PRE group)
Trial: 20415935
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen arginate (POST group)
Trial: 19433378
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of the campaign and a cognitive-behavioral small group intervention
Trial: 14983952
Drug: Screening with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening with transrectal ultrasonography (TRUS) and sextant prostate biopsy when PSA >4 ng/mL (or >2.9 ng/mL after May 1998)
Trial: 10919682
Drug: Salbutamol 200
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 200 microg four times daily via HFA 134a pMDI (Ventolin CFC-free)
Trial: 10919682
Drug: Salbutamol 200
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 200 microg four times daily via CFC pMDI (Ventolin)
Trial: 8639796
Drug: Working Formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Working Formulation (WF) - intermediate/high-grade
Trial: 8639796
Drug: Working Formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Working Formulation (WF) - low-grade
Trial: 29345992
Drug: Substance use
RxNorm normalized name: reSET Substance Use Disorder Therapy Software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance use disorder treatment in jail
Trial: 27650051
Drug: Intramuscular betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular betamethasone (11.4 mg Celestone Chronodose), repeated weekly if risk of very preterm birth remained
Trial: 27650051
Drug: Saline placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo, repeated weekly if risk of very preterm birth remained
Trial: 27650051
Drug: Intramuscular betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular betamethasone (11.4 mg Celestone Chronodose)
Trial: 25024623
Drug: BM‐MNCs transplantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BM‐MNCs transplantation plus routine medical treatment
Trial: 17446823
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment only (Control)
Trial: 16094217
Drug: MMRV (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV (1 dose)
Trial: 16094217
Drug: MMRV (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV (2 doses)
Trial: 16094217
Drug: M‐M‐RII and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M‐M‐RII and VARIVAX (1 dose)
Trial: 12477671
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg dolasetron i.v.
Trial: 12477671
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg metoclopramide i.v.
Trial: 10652047
Drug: Intravenous pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pamidronate (0.5 mg/kg) administered at the time of transplantation and again one month later
Trial: 9037847
Drug: Nisoldipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (10 mg daily)
Trial: 1370735
Drug: Continuous aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous aprotinin infusion (0.1‐0.4 Mill. KIU/hr)
Trial: 1370735
Drug: Continuous aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous aprotinin infusion
Trial: 6380717
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of radiotherapy and local external hyperthermia
Trial: 6380717
Drug: Immediate combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate combination of heat and large radiation fractions
Trial: 6380717
Drug: Highest hyperthermic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest hyperthermic treatment and largest radiation fractions
Trial: 29241357
Drug: CBD (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (1000 mg/day)
Trial: 9028551
Drug: Intravenous CMV
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CMV hyperimmune globulin (0.4 g/kg on day -8, 0.2 g/kg on days -1, +7, +14, +21, +28, +35, +42, +56, +70)
Trial: 11136142
Drug: Lidocaine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (2 mg/kg)
Trial: 31755634
Drug: Screening and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening and treatment for HCV
Trial: 31301054
Drug: CoQun® (ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQun® (ophthalmic solution of Coenzyme Q10 and Vitamin E)
Trial: 28489775
Drug: Nimodipine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 7.5 μg/(kg × h) injected 30 minutes before anesthesia induction
Trial: 21565138
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with Kangliu Zengxiao Decoction (KLZX)
Trial: 21565138
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with KLZX
Trial: 11014951
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone (200 mg/day)
Trial: 11014951
Drug: Intravenous albumin
RxNorm normalized name: albumin human, USP Injection [Albuminar]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous albumin (100 ml of 20%)
Trial: 9241103
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 1 g day(‐1) for 4 weeks
Trial: 24956496
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (telaprevir, ribavirin, pegylated-interferon alfa)
Trial: 24956496
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (boceprevir, ribavirin, pegylated-interferon alfa)
Trial: 22079391
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (Q10) supplementation at a dose of 90 mg daily for 8 weeks
Trial: 18386567
Drug: Rhubarb combined
RxNorm normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb combined with enteral nutrition (10% rhubarb liquid medication, 100 mL before operation, 50 mL at 18th and 42th hour post-operation)
Trial: 18386567
Drug: Conventional fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fluid supplement and parenteral nutrition
Trial: 12537464
Drug: Moderate beer
RxNorm normalized name: BEER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate beer consumption (330 mL of beer/day for 30 days)
Trial: 8340155
Drug: Ridogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridogrel (300 mg)
Trial: 3032537
Drug: Guar administration
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar administration (5-g minitablets, three times per day with main meals for 8 weeks)
Trial: 3032537
Drug: Guar administration
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar administration
Trial: 31522924
Drug: Smartphone application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone application (app) for reporting symptoms, used weekly or sooner if symptoms worsened
Trial: 31337168
Drug: Interfascial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interfascial injection (IF Group)
Trial: 31337168
Drug: Perivascular injection
RxNorm normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perivascular injection with nerve stimulation (PV Group)
Trial: 27337795
Drug: 10 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 Hz rTMS delivered to the left dorsolateral prefrontal cortex, 2 times daily for 10 days
Trial: 23819344
Drug: Fixed-dose perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose perindopril and amlodipine combination
Trial: 16614584
Drug: Fast-track treatment
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-track treatment
Trial: 10765092
Drug: Orchiectomy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orchiectomy combined with adjuvant mitomycin C (MMC; 15 mg/m(2) i.v. q 6 weeks)
Trial: 8889684
Drug: Ethanol (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0, 0.28, 0.52 g/kg)